300878 维康药业
已收盘 07-26 15:00:00
资讯
新帖
简况
维康药业最新公告：拟转让全资孙公司维康零售100%股权、维康大药房100%股权
证券之星 · 07-23
维康药业最新公告：拟转让全资孙公司维康零售100%股权、维康大药房100%股权
维康药业(300878.SZ)拟出售维康零售、维康大药房100%股权 聚焦医药制造业
智通财经网 · 07-23
维康药业(300878.SZ)拟出售维康零售、维康大药房100%股权 聚焦医药制造业
维康药业：公司将灵芝孢子粉作为战略打造的大单品，对该产品的推广投入较大
证券之星 · 07-15
维康药业：公司将灵芝孢子粉作为战略打造的大单品，对该产品的推广投入较大
维康药业：公司在天猫、京东、拼多多等电商平台设有官方旗舰店，消费者可自行选购公司产品
证券之星 · 07-09
维康药业：公司在天猫、京东、拼多多等电商平台设有官方旗舰店，消费者可自行选购公司产品
维康药业业绩变脸背后：“神奇”的在建工程与供应商消失之“谜”
钛媒体APP · 06-18
维康药业业绩变脸背后：“神奇”的在建工程与供应商消失之“谜”
维康药业(300878.SZ)收到银黄滴丸Ⅱb期临床试验总结报告
智通财经 · 06-17
维康药业(300878.SZ)收到银黄滴丸Ⅱb期临床试验总结报告
维康药业：股东刘忠姣所持987.20万股解除质押 占公司总股本比例6.82%
中国财富通 · 06-04
维康药业：股东刘忠姣所持987.20万股解除质押 占公司总股本比例6.82%
维康药业拟出售医药零售和大药房业务 集中优势资源聚焦医药制造业
中证网 · 05-30
维康药业拟出售医药零售和大药房业务 集中优势资源聚焦医药制造业
维康药业因业绩预测结果不准确或不及时等违规行为被深圳证券交易所采取监管措施
证券之星 · 05-28
维康药业因业绩预测结果不准确或不及时等违规行为被深圳证券交易所采取监管措施
维康药业因业绩预测结果不准确或不及时等违规行为被证监会出具警示函
证券之星 · 05-28
维康药业因业绩预测结果不准确或不及时等违规行为被证监会出具警示函
维康药业最新公告：全资子公司维康商业拟出售维康零售及维康大药房100%股权
证券之星 · 05-27
维康药业最新公告：全资子公司维康商业拟出售维康零售及维康大药房100%股权
维康药业(300878.SZ)及相关人员收到浙江证监局警示函
智通财经网 · 05-27
维康药业(300878.SZ)及相关人员收到浙江证监局警示函
聚焦医药制造业 维康药业(300878.SZ)筹划出售2家零售连锁业务子公司
智通财经 · 05-27
聚焦医药制造业 维康药业(300878.SZ)筹划出售2家零售连锁业务子公司
维康药业收年报问询函 上市次年起净利持续下滑
北京商报 · 05-23
维康药业收年报问询函 上市次年起净利持续下滑
维康药业（300878）4月26日主力资金净卖出703.42万元
证券之星 · 04-29
维康药业（300878）4月26日主力资金净卖出703.42万元
图解维康药业年报：第四季度单季净利润同比减71.52%
证券之星 · 04-29
图解维康药业年报：第四季度单季净利润同比减71.52%
维康药业(300878.SZ)发布2023年度业绩，净亏损803.86万元，同比盈转亏
智通财经 · 04-28
维康药业(300878.SZ)发布2023年度业绩，净亏损803.86万元，同比盈转亏
维康药业(300878.SZ)发布一季度业绩，净利润2433万元，同比下降11.59%
智通财经 · 04-28
维康药业(300878.SZ)发布一季度业绩，净利润2433万元，同比下降11.59%
维康药业最新公告：一季度净利润2433.5万元 同比下降11.6%
证券之星 · 04-28
维康药业最新公告：一季度净利润2433.5万元 同比下降11.6%
公司概况
公司名称：
浙江维康药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-08-24
主营业务：
浙江维康药业股份有限公司主营业务为现代中药及西药的研发、生产和销售，主要产品包括银黄滴丸、骨刺胶囊、枫蓼肠胃康分散片、益母草软胶囊等中成药以及罗红霉素软胶囊等西药，生产剂型包括硬胶囊剂、片剂、颗粒剂、软胶囊剂、丸剂（滴丸）。
发行价格：
41.34
{"stockData":{"symbol":"300878","market":"SZ","secType":"STK","nameCN":"维康药业","latestPrice":14.15,"timestamp":1721977383000,"preClose":13.97,"halted":0,"volume":638500,"delay":0,"floatShares":77742500,"shares":145000000,"eps":-0.0776,"marketStatus":"已收盘","marketStatusCode":5,"change":0.18,"latestTime":"07-26 15:00:00","open":13.98,"high":14.18,"low":13.93,"amount":8993700,"amplitude":0.0179,"askPrice":14.15,"askSize":33,"bidPrice":14.13,"bidSize":23,"shortable":0,"etf":0,"ttmEps":-0.0776,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"adjPreClose":13.97,"symbolType":"stock","openAndCloseTimeList":[[1721957400000,1721964600000],[1721970000000,1721977200000]],"highLimit":15.37,"lowLimit":12.57,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":144790322,"pbRate":1.48,"roa":"--","roe":"1.75%","epsLYR":-0.06,"committee":0.407202,"marketValue":2049000000,"floatMarketCap":1100000000,"peRate":-182.345355,"changeRate":0.0129,"turnoverRate":0.0082,"status":0},"requestUrl":"/m/hq/s/300878/wiki","defaultTab":"wiki","newsList":[{"id":"2453080758","title":"维康药业最新公告：拟转让全资孙公司维康零售100%股权、维康大药房100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2453080758","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453080758?lang=zh_cn&edition=full","pubTime":"2024-07-23 19:21","pubTimestamp":1721733662,"startTime":"0","endTime":"0","summary":"维康药业公告，公司拟转让全资孙公司浙江维康医药零售有限公司（“维康零售”）100%股权给福建融创二号投资有限公司，转让全资孙公司浙江维康大药房有限公司（“维康大药房”）100%股权给福建融创三号投资有限公司。此次交易完成后，公司不再持有维康零售、维康大药房股份，维康零售、维康大药房将不再纳入公司合并报表范围。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300036932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2453508044","title":"维康药业(300878.SZ)拟出售维康零售、维康大药房100%股权 聚焦医药制造业","url":"https://stock-news.laohu8.com/highlight/detail?id=2453508044","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453508044?lang=zh_cn&edition=full","pubTime":"2024-07-23 19:16","pubTimestamp":1721733378,"startTime":"0","endTime":"0","summary":"维康药业(300878.SZ)公告，公司拟拟转让全资孙公司维康零售100%股权给福...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/20.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/20.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09939","BK1574","BK6054","WJP.SI","BK1161","300878","BK0239","159938","BK6520","BK1515"],"gpt_icon":0},{"id":"2451619335","title":"维康药业：公司将灵芝孢子粉作为战略打造的大单品，对该产品的推广投入较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2451619335","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451619335?lang=zh_cn&edition=full","pubTime":"2024-07-15 17:06","pubTimestamp":1721034391,"startTime":"0","endTime":"0","summary":"证券之星消息，维康药业07月15日在投资者关系平台上答复投资者关心的问题。根据碧湾APP分析，2024年一季度主营业务利润为2,606.46万元，去年同期为3,064.20万元，同比小幅下降14.94%的原因是销售费用本期为5233.69万元，同比增长30.78%。公司将灵芝孢子粉作为战略打造的大单品，对该产品的推广投入较大。此外，市场竞争愈加激烈，公司为促进销售业务，增加产品推广费用。感谢您对公司的关注，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500022986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2450011408","title":"维康药业：公司在天猫、京东、拼多多等电商平台设有官方旗舰店，消费者可自行选购公司产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2450011408","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450011408?lang=zh_cn&edition=full","pubTime":"2024-07-09 18:06","pubTimestamp":1720519568,"startTime":"0","endTime":"0","summary":"证券之星消息，维康药业(300878)07月09日在投资者关系平台上答复投资者关心的问题。投资者：董秘您好，请问贵公司生产的药品，有没有通过电商渠道或者直播服务，促进产品的销售？谢谢！维康药业董秘：尊敬的投资者，您好！公司在天猫、京东、拼多多等电商平台设有官方旗舰店，消费者可自行选购公司产品。感谢您对公司的关注，谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900039978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0140636845.USD","LU0228659784.USD","LU0127658192.USD","LU0708995583.HKD","LU0348825331.USD","LU0543330483.HKD","LU1282649067.USD","LU0039217434.USD","LU0327786744.USD","LU0307460666.USD","BK1249","LU0370786039.SGD","09618","IE00B0JY6N72.USD","LU0672654166.SGD","LU1366334651.USD","LU0326950275.SGD","IE00B3M56506.USD","LU0359202008.SGD","LU0229945570.USD","LU0214875030.USD","LU1282649810.SGD","LU0456842615.SGD","BK1517","89618","BK1575","LU0228367735.SGD","300878","IE00B5MMRT66.SGD","LU0348805143.USD","BK1591","LU0456827905.SGD","LU0348784397.USD","LU0588545490.SGD","BK1586","BK1501","LU0029875118.USD","LU0072462343.USD","BK1610","BK1502","09988","LU0588546209.SGD","LU0572944931.SGD","LU1044876610.USD","LU0456846285.SGD","BK1584","89988","IE00BMPRXN33.USD"],"gpt_icon":0},{"id":"2444107901","title":"维康药业业绩变脸背后：“神奇”的在建工程与供应商消失之“谜”","url":"https://stock-news.laohu8.com/highlight/detail?id=2444107901","media":"钛媒体APP","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444107901?lang=zh_cn&edition=full","pubTime":"2024-06-18 18:11","pubTimestamp":1718705460,"startTime":"0","endTime":"0","summary":"对此，深交所要求公司说明毛利率下滑的原因，与同行业可比公司是否一致。其中，医药制造企业2023年3家企业保持毛利率上涨，而从变动幅度来看，除公司之外，其余企业医药制造部分毛利率变动幅度均在2%之内。“神奇”的在建工程经公司自查，2020年第四季度至2023年，公司实控人刘忠良通过工程供应商以公司支付工程设备款方式累计占用公司资金1.42亿元，其中0.56亿元用于归还其个人借款，剩余资金由其直接占用。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/cj/2024-06-18/doc-inazczxh3711731.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2024-06-18/doc-inazczxh3711731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2444176130","title":"维康药业(300878.SZ)收到银黄滴丸Ⅱb期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2444176130","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444176130?lang=zh_cn&edition=full","pubTime":"2024-06-17 15:48","pubTimestamp":1718610518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业(300878.SZ)公告，公司近日收到银黄滴丸治疗复发性口腔溃疡(上焦实热证)的有效性和安全性的多中心、随机、双盲、安慰剂平行对照Ⅱb期临床试验的总结报告。研究结果初步显示，银黄滴丸治疗复方性口腔溃疡(上焦实热证)疗效显著，临床使用安全性良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300878","03347","BK1576","BK1141","BK1583","BK0239"],"gpt_icon":0},{"id":"2440920407","title":"维康药业：股东刘忠姣所持987.20万股解除质押 占公司总股本比例6.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440920407","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440920407?lang=zh_cn&edition=full","pubTime":"2024-06-04 17:36","pubTimestamp":1717493761,"startTime":"0","endTime":"0","summary":"中国财富通6月4日 - 维康药业（300878）公告称，公司近日接到公司股东刘忠姣的通知，获悉其所持有的本公司股份办理了解除质押手续，本次解除质押股数987.20万股，占公司总股本比例6.82%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=9qqA%2FO7%2FyaY%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2439462306","title":"维康药业拟出售医药零售和大药房业务 集中优势资源聚焦医药制造业","url":"https://stock-news.laohu8.com/highlight/detail?id=2439462306","media":"中证网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439462306?lang=zh_cn&edition=full","pubTime":"2024-05-30 20:32","pubTimestamp":1717072320,"startTime":"0","endTime":"0","summary":" 维康药业于2020年8月在创业板上市，主营业务为现代中药及西药的研发、生产和销售，即医药制造业，同时还经营医药商业产品的零售连锁等流通业务作为主营业务的补充。另据公司2023年年报显示，维康大药房和维康医药零售营收规模和占比、毛利率均低于医药制造业。 维康药业在公告中表示，通过本次股权出售，有利于公司集中优势资源聚焦医药制造业，继续推进现代中药及西药的协同发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-05-30/doc-inawzmfp0296734.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-05-30/doc-inawzmfp0296734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","BK1515","BK0239","BK1574","000145.SH","300878","BK1161"],"gpt_icon":0},{"id":"2438332675","title":"维康药业因业绩预测结果不准确或不及时等违规行为被深圳证券交易所采取监管措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2438332675","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438332675?lang=zh_cn&edition=full","pubTime":"2024-05-28 01:00","pubTimestamp":1716829239,"startTime":"0","endTime":"0","summary":"证券之星消息，5月27日维康药业公开信息显示，浙江维康药业股份有限公司，副总经理孔晓霞、非独立董事朱婷、财务总监王静、刘忠良因业绩预测结果不准确或不及时,未依法履行其他职责被深圳证券交易所创业板公司管理部采取监管措施。详细违规行为如下：2024年4月29日,公司披露的《2023年年度报告》显示,公司2023年度实现归属于上市公司股东的净利润为-803.86万元。公司未按规定在会计年度结束之日起一个月内进行业绩预告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800000190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399001","300878","BK0239"],"gpt_icon":0},{"id":"2438326293","title":"维康药业因业绩预测结果不准确或不及时等违规行为被证监会出具警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2438326293","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438326293?lang=zh_cn&edition=full","pubTime":"2024-05-28 01:00","pubTimestamp":1716829238,"startTime":"0","endTime":"0","summary":"证券之星消息，5月27日维康药业公开信息显示，浙江维康药业股份有限公司，副总经理孔晓霞、非独立董事朱婷、财务总监王静、刘忠良因业绩预测结果不准确或不及时,未依法履行其他职责被中国证券监督管理委员会浙江监管局出具警示函。详细违规行为如下：浙江维康药业股份有限公司于2024年4月29日披露的《2023年年度报告》显示,公司2023年度归属于上市公司股东的净利润为亏损803.86万元,公司未按规定及时披露2023年度业绩预告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800000188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2438410389","title":"维康药业最新公告：全资子公司维康商业拟出售维康零售及维康大药房100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2438410389","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438410389?lang=zh_cn&edition=full","pubTime":"2024-05-27 20:20","pubTimestamp":1716812457,"startTime":"0","endTime":"0","summary":"维康药业公告，全资子公司维康商业与浙江康佰家签署股权收购意向书，拟出售所持维康零售及维康大药房100%股权。浙江康佰家将以现金支付方式购买，交易尚在筹划阶段，具体方案待协商。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052700026114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2438389170","title":"维康药业(300878.SZ)及相关人员收到浙江证监局警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2438389170","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438389170?lang=zh_cn&edition=full","pubTime":"2024-05-27 20:19","pubTimestamp":1716812385,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业 公告，公司及相关责任人员于2024年5月27日收到中国证券监督管理委员会浙江监管局出具的《关于对浙江维康药业股份有限公司及相关责任人员采取出具警示函措施的决定》。据悉，公司于2024年4月29日披露的《2023年年度报告》显示，公司2023年度归属于上市公司股东的净利润为亏损803.86万元，公司未按规定及时披露2023年度业绩预告。根据规定，浙江证监局决定对公司及上述人员分别采取出具警示函的监督管理措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2438338933","title":"聚焦医药制造业 维康药业(300878.SZ)筹划出售2家零售连锁业务子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2438338933","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438338933?lang=zh_cn&edition=full","pubTime":"2024-05-27 20:12","pubTimestamp":1716811961,"startTime":"0","endTime":"0","summary":"目前标的公司的主要业务为零售连锁业务，即通过向上游公司采购药品、医疗器械等，通过零售渠道向终端消费者进行销售。通过本次股权出售，有利于公司集中优势资源聚焦医药制造业，继续推进现代中药及西药的协同发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300878","BK1161","BK1515","159938","09939","BK1574"],"gpt_icon":0},{"id":"2437751565","title":"维康药业收年报问询函 上市次年起净利持续下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2437751565","media":"北京商报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437751565?lang=zh_cn&edition=full","pubTime":"2024-05-23 20:45","pubTimestamp":1716468300,"startTime":"0","endTime":"0","summary":"股价一路下跌背后，从上市次年起，维康药业归属净利润出现持续下滑，2023年更是出现亏损。5月23日晚间，维康药业收到了深交所下发的年报问询函，就公司业绩情况展开追问。把时间拉长来看，维康药业自2021年起净利开始逐年下滑。这一情况也受到了深交所的关注，深交所要求维康药业详细分析公司净利润自上市次年起连续下滑的原因，与同行业可比公司变动趋势是否一致。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-05-23/doc-inawfpks8176620.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-05-23/doc-inawfpks8176620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2431904675","title":"维康药业（300878）4月26日主力资金净卖出703.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431904675","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431904675?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:21","pubTimestamp":1714353708,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月26日收盘，维康药业报收于16.86元，下跌2.88%，换手率3.17%，成交量2.46万手，成交额4206.69万元。近5日资金流向一览见下表：维康药业融资融券信息显示，融资方面，当日融资买入310.66万元，融资偿还184.18万元，融资净买入126.48万元。维康药业主营业务：现代中药及西药的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900002447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2431060536","title":"图解维康药业年报：第四季度单季净利润同比减71.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431060536","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431060536?lang=zh_cn&edition=full","pubTime":"2024-04-29 00:32","pubTimestamp":1714321953,"startTime":"0","endTime":"0","summary":"证券之星消息，维康药业2023年年报显示，公司主营收入5.2亿元，同比下降2.41%；归母净利润-803.86万元，同比下降116.47%；扣非净利润-2521.75万元，同比下降206.98%；其中2023年第四季度，公司单季度主营收入8761.94万元，同比上升50.83%；单季度归母净利润-7738.92万元，同比下降71.52%；单季度扣非净利润-8932.72万元，同比下降58.59%；负债率31.23%，投资收益1386.79万元，财务费用756.21万元，毛利率50.39%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900000179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878"],"gpt_icon":0},{"id":"2430059621","title":"维康药业(300878.SZ)发布2023年度业绩，净亏损803.86万元，同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2430059621","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430059621?lang=zh_cn&edition=full","pubTime":"2024-04-28 20:11","pubTimestamp":1714306308,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业(300878.SZ)发布2023年度报告，该公司报告期实现营业收入5.2亿元，同比减少2.41%。归属于上市公司股东的净亏损803.86万元，同比盈转亏。归属于上市公司股东的扣除非经常性损益的净亏损2521.75万元，同比盈转亏。基本每股收益-0.06元/股，拟向全体股东每10股派发现金红利2.50元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2430053095","title":"维康药业(300878.SZ)发布一季度业绩，净利润2433万元，同比下降11.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430053095","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430053095?lang=zh_cn&edition=full","pubTime":"2024-04-28 19:30","pubTimestamp":1714303837,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业(300878.SZ)披露2024年第一季度报告，报告期公司实现营收2亿元，同比增长2.15%;归母净利润2433万元，同比下降11.59%;扣非净利润2003万元，同比下降8.74%。基本每股收益0.17元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300878"],"gpt_icon":0},{"id":"2430034639","title":"维康药业最新公告：一季度净利润2433.5万元 同比下降11.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430034639","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430034639?lang=zh_cn&edition=full","pubTime":"2024-04-28 17:53","pubTimestamp":1714298029,"startTime":"0","endTime":"0","summary":"维康药业发布2024年第一季度报告，实现营业收入2亿元，同比增长2.15%；归属于上市公司股东的净利润2433.5万元，同比下降11.59%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800006763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-08-24","address":"浙江省丽水市莲都区经济开发区遂松路2号","stockEarnings":[{"period":"1week","weight":-0.0176},{"period":"1month","weight":-0.0272},{"period":"3month","weight":-0.1587},{"period":"6month","weight":-0.352},{"period":"1year","weight":-0.391},{"period":"ytd","weight":-0.4409}],"companyName":"浙江维康药业股份有限公司","boardCode":"AI0027","perCapita":"5867股","boardName":"医药制造业","registeredCapital":"14479万元","compareEarnings":[{"period":"1week","weight":-0.0304},{"period":"1month","weight":-0.0214},{"period":"3month","weight":-0.0654},{"period":"6month","weight":-0.0081},{"period":"1year","weight":-0.1043},{"period":"ytd","weight":-0.0296}],"survey":" 浙江维康药业股份有限公司主营业务为现代中药及西药的研发、生产和销售，主要产品包括银黄滴丸、骨刺胶囊、枫蓼肠胃康分散片、益母草软胶囊等中成药以及罗红霉素软胶囊等西药，生产剂型包括硬胶囊剂、片剂、颗粒剂、软胶囊剂、丸剂（滴丸）。","serverTime":1721996316839,"listedPrice":41.34,"stockholders":"13250人(较上一季度减少13.22%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维康药业(300878)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维康药业(300878)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维康药业,300878,维康药业股票,维康药业股票老虎,维康药业股票老虎国际,维康药业行情,维康药业股票行情,维康药业股价,维康药业股市,维康药业股票价格,维康药业股票交易,维康药业股票购买,维康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维康药业(300878)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维康药业(300878)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}